



Integrating High Throughput Transcriptomics into a Tiered Framework to Prioritize Chemicals for Toxicity Testing

J. D. Rogers^{1,2}, K. Paul-Friedman¹, L. J. Everett¹

1. Center for Computational Toxicology and Exposure, Office of Research and Development, U.S. EPA, Research Triangle Park, NC
2. Oak Ridge Institute for Science and Education, Oak Ridge, TN

The views expressed in this presentation are those of the authors and do not necessarily represent the views or policies of the Agency.

Jesse Rogers | rogers.jesse@epa.gov | ID 0000-0001-6667-2342

Background and Objectives

Study Background:

- 1000s of chemicals currently used in USA for commercial non-food/drug applications (<https://www.epa.gov/tsca-inventory>)
- Current toxicity testing requires multi-year animal studies, costing >\$1 million per substance
- High-Throughput Transcriptomics (HTTr): broad-coverage assay for 1000s of chemicals in concentration-response format (Harrill et al. *ToxSci* 2021)
- High-Throughput Screening (HTS): measurement of alterations in key molecular targets via US EPA ToxCast program (Richard et al. *CRT* 2016)
- Computational integration of HTTr/HTS data streams for assessing key hazards is needed for further adoption in regulatory applications


Study Objectives:

- Generate new signatures from HTTr screening data representing putative mechanisms-of-action (MoAs)
- Develop framework for validating HTTr signature results using HTS data streams
- Apply framework to current screening HTTr screening data to identify candidate modulators of key MoAs

Reference Signature Development


1) Assign Reference Chemicals to Putative MoAs:

- RefChemDB*: curated literature associations of chemical-target pairs (Judson et al. *ALTEX* 2019)
- Hierarchical clustering of similarly-represented targets (Bundy et al. *BioData Mining* 2022)
- Chemical-cluster assignment: $\text{Max}(\sum \text{Support}_{\text{cluster}})$




2) Estimate Chemical Potency from HTTr Screening Data:

- 1218 chemicals screened in 8-point concentration response via TempO-Seq platform in HepaRG and U-2 OS cell lines (Yeakley et al. *PLOS ONE* 2017, Harrill et al. *Tox Sci* 2021)
- Benchmark Doses (BMDs) for DESeq2-moderated log2(FC) values estimated via *topofit2* (Sheffield et al. *Bioinformatics* 2022)



3) Generate Reference Signatures from HTTr Potency Estimates:

- Apply univariate potency analysis to select genes uniquely potent for individual reference chemical sets:




- One Way ANOVA:**
- $\log_{10}(\text{BMD})_{\text{Gene}_i} \sim \text{Class}$
 - FDR < 0.05
- Apply Criteria:**
- $\log_{10}(\text{BMD})$ lower than other classes
 - $p < 0.05$ against 9 of 12 other classes
 - Gene meets criteria for only 1 class

U.S. Environmental Protection Agency
Office of Research and Development

Reference Signatures Distinguish MoAs


Gene-level comparison:

Hierarchical clustering of gene BMDs reveals distinct potencies of reference chemicals towards selected genes



Distinct signatures across cell lines suggest need for profiling across multiple model systems

- Signature-level comparison:** Concentration-response modeling via *CompTox-httrpathway* R package (<https://github.com/USEPA/CompTox-httrpathway>)
- Enrichment score estimation via ssGSEA (Barbie et al. *Nature* 2009)
 - BMD estimation via *topofit2*, bioactivity determined by thresholding of hitcall and efficacy metrics (left)
 - Randomization test against 250 randomly-generated signatures confirms ability of reference signatures to distinguish positive reference chemicals (right)



Passed bioactivity thresholds
+ FALSE
• TRUE


Chemical in reference class
• FALSE
• TRUE

Reference Signature Difference of Means

Integration of Transcriptomics into Chemical Prioritization Framework

Primary Assessment Aim:


Prioritize chemicals with selective effects on molecular targets across transcriptional and receptor-level readouts by comparing targeted points of departure (PODs) against non-selective PODs



- Non-selective PODs estimated from BMDs for >10,000 publicly-sourced signatures (HTTr) or all measured ToxCast endpoints (HTS) (Judson et al. *Tox Sci* 2016)
- Selectivity thresholds established for individual chemicals: $\text{Mode}(\text{BMD}_{\text{nonselective}}) - \sigma(\text{BMD}_{\text{nonselective}})$

HTS Confirmation of HTTr Predictions

- Candidates designated as bioactive via HTTr show increased probability of bioactivity in orthogonal HTS assays via Fisher's exact tests:




- Individual candidates predicted as selective for individual MoAs in both HTTr/HTS represent known chemical classes or drugs for each target:


AHR Agonist Candidates:
Anthraquinone derivatives indicate detection of similar aromatic features to known agonists, e.g. PAHs

NR3C1 Agonist Candidates:
Prescribed synthetic glucocorticoids prioritized alongside minor agonists

AHR HTS Assays: Transcription Factor Activity (ATG) and Receptor Activation (TOX21)




NR3C1 HTS Assays: Transcription Factor Activity (ATG) and Receptor Activation (TOX21)




Comparison to Previous in vitro PODs

- Previous HTTr Overall POD:** 5th percentile BMD of bioactive signatures from >10,000 publicly-sourced signature catalog
- 80.0 ± 1.72% of bioactive chemicals demonstrate MoA-specific signature BMD within ± 0.5-log units of overall POD or below



- Previous HTS Overall POD:** 5th percentile BMD of bioactive endpoints from all measured ToxCast endpoints
- 20.1 ± 13.7% of bioactive chemicals demonstrate MoA-specific signature BMD within ± 0.5-log units of overall POD or below
- Narrow distribution of HTTr BMDs versus ToxCast consistent with previous transcriptional PODs



Conclusions

- Univariate gene identification strategy paired with signature concentration response analysis allows for assessment of putative MoAs from HTTr screening data
- Confirmation of transcriptional bioactivity via targeted HTS assays identifies selectively-acting environmental chemicals and pharmaceuticals
- Future testing of data-poor chemicals can be informed by broad-coverage assays for efficient chemical assessment